Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs REGN 1908-1909 (Primary)
  • Indications Allergic asthma; Allergic conjunctivitis; Allergic rhinitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

    • Most Recent Events

    • 27 Feb 2023 Results assessing the effect of a single dose of Felisdomesticus allergen 1 monoclinal antibodies REGN-1908-1909 on asthma signatures in a clinical trial assessing efficacy of the antibodies for prevention of early asthma responses by cat allergen in cat allergic mild asthmatic subjects, presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 01 Mar 2021 Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 27 Feb 2021 Primary endpoint (Time to Early asthmatic response (EAR) upon Controlled Cat Allergen Challenge in an Environmental exposure unit (EEU)) has been met, according to a Regeneron Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top